Novartis's Onbrez Breezhaler approved in EU for COPD
This article was originally published in Scrip
Novartis's bronchodilator Onbrez Breezhaler (indacaterol; formerly QAB149) has been approved in the EU as a once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, following a positive CHMP opinion in September.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.